ZeroStack (ZSTK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 May, 2026Executive summary
The annual and special meeting is scheduled for July 13, 2026, to address key proposals including director elections, auditor re-appointment, equity issuances, compensation plan amendments, stock option grants, corporate continuance to Texas, board classification, and potential adjournments.
Shareholders of record as of May 20, 2026, are entitled to vote, with one vote per common share on each matter.
The board recommends voting in favor of all proposals, emphasizing alignment with Nasdaq rules and corporate governance best practices.
Forward-looking statements highlight risks related to digital assets, regulatory compliance, AI, and the planned continuance to Texas.
Voting matters and shareholder proposals
Proposals include electing five directors, re-appointing Davidson & Company LLP as auditors, approving a PIPE offering issuance, amending the 2022 Incentive Compensation Plan, granting executive stock options, authorizing continuance to Texas, classifying the board, and allowing adjournments.
Each proposal requires either a simple majority or, for continuance, a two-thirds majority of votes cast.
Shareholders can vote in person, by proxy, or online, with detailed instructions provided.
Shareholder proposals for the 2027 meeting must be submitted by February 3, 2027.
Board of directors and corporate governance
The board consists of five directors, with a mix of executive and independent members, and three standing committees: Audit, Compensation, and Nominating and Corporate Governance.
Proposal to classify the board into three staggered classes to enhance continuity and stability.
The board has adopted a Code of Conduct and Ethics, and orientation and continuing education programs for directors.
No family relationships or recent legal proceedings involving directors.
Latest events from ZeroStack
- Shareholders will vote on director elections, compensation, equity plans, and moving incorporation to Texas.ZSTK
Proxy filing8 May 2026 - Q1 2026 saw higher revenue but a $36.7M net loss due to digital asset fair value declines.ZSTK
Q1 20264 May 2026 - Net loss surged to $119.7M on digital asset losses as the company pivoted to an AI-focused treasury model.ZSTK
Q4 202527 Feb 2026 - Net loss narrowed to $2.7M as revenue fell and global expansion, cost cuts, and new launches continued.ZSTK
Q2 20242 Feb 2026 - Q3 revenue dropped and net loss widened, but U.S. and German growth prospects remain.ZSTK
Q3 202414 Jan 2026 - Strategic shift to AI and digital assets, with major OG Token holdings and expanded pharma reach.ZSTK
Registration Filing8 Jan 2026 - Registering 3.86M shares for resale; proceeds go to investors, not the company.ZSTK
Registration Filing16 Dec 2025 - 3.2 million shares registered for resale after acquisition and executive grants; no proceeds to issuer.ZSTK
Registration Filing16 Dec 2025 - 3.2 million shares registered for resale; no proceeds to company; global cannabis expansion focus.ZSTK
Registration Filing16 Dec 2025